3PBIOVIAN Marks First Year with Global CDMO Growth and Expansion

• 3PBIOVIAN, formed in 2024 through the merger of BIOVIAN and 3P Biopharmaceuticals, has completed its first year of operations, expanding its global CDMO services.

• The company plans further investments to strengthen its protein and advanced therapy manufacturing capabilities and expand its presence in the U.S. market.

3PBIOVIAN, a contract development and manufacturing organisation (CDMO), has completed its first year following the merger of BIOVIAN and 3P Biopharmaceuticals. With facilities in Noaín, Spain, and Turku, Finland, the company provides process development and manufacturing solutions for recombinant proteins, monoclonal antibodies, plasmids, and advanced therapies.

Over the past year, 3PBIOVIAN has gained new clients and reinforced long-term partnerships, positioning itself as a key player in the biopharmaceutical industry. The company credits its team of more than 500 professionals with driving its growth. Dámaso Molero, CEO of 3PBIOVIAN, stated, “The true strength of our company lies in our people, who have worked tirelessly to create an environment of excellence focused on the customer and their manufacturing needs.”

Looking ahead, 3PBIOVIAN aims to expand its capabilities in protein and advanced therapy manufacturing while strengthening its presence in the United States. The company has outlined a strategic investment plan to address industry challenges and solidify its standing in the competitive CDMO market.